Last reviewed · How we verify
Buspar
At a glance
| Generic name | Buspar |
|---|---|
| Also known as | Buspirone HCl, buspirone HCl |
| Sponsor | Par Pharmaceutical, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (PHASE4)
- Transformation of Paralysis to Stepping (EARLY_PHASE1)
- Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury (PHASE2)
- Buspirone for Anxiety in Autistic Youth (PHASE4)
- Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression (PHASE4)
- Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal (NA)
- Spinal Cord Neuromodulation for Spinal Cord Injury (PHASE1, PHASE2)
- Evaluating Buspirone to Treat Opioid Withdrawal (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buspar CI brief — competitive landscape report
- Buspar updates RSS · CI watch RSS
- Par Pharmaceutical, Inc. portfolio CI